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Abstract: 20 
Objective: Hsa-miR-148a expression is decreased in OA cartilage, but its functional 21 
role in cartilage has never been studied. Therefore, our aim was to investigate the 22 
effects of overexpressing hsa-miR-148a on cartilage metabolism of OA chondrocytes. 23 
Design: OA chondrocytes were transfected with a miRNA precursor for hsa-miR-24 
148a or a miRNA precursor negative control. After 3, 7, 14 and 21 days, real-time 25 
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PCR was performed to examine gene expression levels of aggrecan (ACAN), type I, 1 
II, and X collagen (COL1A1, COL2A1, COl10A1), matrix metallopeptidase 13 2 
(MMP13), a desintegrin and metalloproteinase with thrombospondin motifs 5 3 
(ADAMTS5) and the serpin peptidase inhibitor, clade H (heat shock protein 47), 4 
member 1 (SERPINH1). After 3 weeks, DNA content and proteoglycan and collagen 5 
content and release were determined. Type II collagen was analyzed at the protein 6 
level by Western blot.  7 
Results: Overexpression of hsa-miR-148a had no effect on ACAN, COL1A1 and 8 
SERPINH1 gene expression, but increased COL2A1 and decreased COL10A1, 9 
MMP13 and ADAMTS5 gene expression. Luciferase reporter assay confirmed direct 10 
interaction of miR-148a and COL10A1, MMP13 and ADAMTS5. The matrix 11 
deposited by the miR-148a overexpressing cells contained more proteoglycans and 12 
collagen, in particular type II collagen. Proteoglycan and collagen release into the 13 
culture medium was inhibited, but total collagen production was increased. 14 
Conclusion: Overexpression of hsa-miR-148a inhibits hypertrophic differentiation 15 
and increases the production and deposition of type II collagen by OA chondrocytes, 16 
which is accompanied by an increased retention of proteoglycans. Hsa-miR-148a 17 
might be a potential disease-modifying compound in OA, as it promotes hyaline 18 
cartilage production. 19 
 20 
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Introduction 1 
Osteoarthritis (OA) is a major cause of physical disability due to symptoms as pain, 2 
stiffness and loss of mobility. Multiple factors are believed to cause OA, such as 3 
trauma, abnormal mechanical loading, failure of nutrient supply and genetic 4 
predisposition (1). Available treatments are limited to pain management and in end-5 
stage OA patients, joint replacement surgery is often indicated. OA is characterized 6 
by local inflammation, synovitis and proteolytic degradation of cartilage, which 7 
correlates with alterations in chondrocyte expression levels of genes involved in 8 
synthesis and degradation of cartilage (1-4). 9 
Recently, it was proposed that epigenetic mechanisms play a role in modulating cell 10 
phenotype in OA (5-10), resulting in permanent changes in DNA transcription. One of 11 
the epigenetic mechanisms involved is based on microRNA (miRNA) expression 12 
(6,8). MiRNAs are short (19-24 nucleotide long) non-coding RNA molecules that can 13 
silence gene expression by binding to complementary sequences on target messenger 14 
RNA transcripts, resulting in translational repression or target degradation. 15 
Approximately one-third of all mammalian genes are regulated by miRNAs (11). 16 
Changes in miRNA expression patterns are found in many pathological conditions, 17 
including several malignancies and neurological, cardiovascular and developmental 18 
diseases (12-16). The role of miRNAs in joint homeostasis has become evident from 19 
studies showing major abnormalities in cartilage development and structure in Dicer-20 
null mice (17). The miRNA expression pattern is also changed in OA and several 21 
miRNAs, including hsa-miR-27, 140, 145, 146a and 675 were found to be associated 22 
with altered levels of cartilage matrix production and degradation (18-29). Although 23 
the involvements of the abovementioned miRNAs in OA were analysed, the effects of 24 
modulating these miRNAs on cartilage regeneration, in particular at the protein level, 25 
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is unknown.  1 
Typically, studies on the possible involvement of miRNAs in pathological processes 2 
start with miRNA screens to identify potential candidates. Previously, screens of 365 3 
and 115 miRNAs, respectively, were profiled in normal and OA cartilage (18,19). In 4 
the scope of performing a more extensive miRNA screen, we found that hsa-miR-5 
148a was expressed at 10.6 times lower levels in OA cartilage compared to normal 6 
cartilage (unpublished observations), in line with previously published results (19). 7 
However, the functional role of hsa-miR-148a in cartilage metabolism or specifically 8 
OA has never been studied. Hsa-miR-148a has some predicted targets that are 9 
relevant for OA and general chondrocyte biology. Amongst the predicted targets are 10 
the messenger RNAs (mRNA) for type II collagen (COL2A1), type X collagen 11 
(COL10A1), matrix metallopeptidase 13 (MMP13), A desintegrin and 12 
metalloproteinase with thrombospondin motifs 5 (ADAMTS5) and the collagen 13 
chaperone serpin peptidase inhibitor, clade H (heat shock protein 47), member 1 14 
(SERPINH1) (30). Therefore, the aim of this study was to investigate the effects of 15 
overexpressing hsa-miR-148a on cartilage metabolism of OA chondrocytes during 16 
regeneration. 17 
 18 
 19 
Materials and methods 20 
 21 
miRNA expression screen 22 
Total RNA was isolated from articular cartilage with the mirVana miRNA isolation 23 
kit (Ambion, Austin, Tx) according to the manufacturer’s protocol. Healthy human 24 
cartilage from femoral condyles of knee joints was obtained post-mortem of 3 male 25 
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donors and 4 female donors, the mean age was 65 years (range: 47 years – 83 years). 1 
OA cartilage was obtained from 3 male and 4 female donors (age 53 to 80, average 69 2 
years) undergoing total knee arthroplasty. cDNA was synthesized using TaqMan 3 
MicroRNA Reverse Transcription Kit (Applied Biosystems, Life technologies, 4 
Poland) with Megaplex RT Primers, Human Pool A and B v3.0 according to the 5 
manufacturer’s protocol. The TaqMan low-density Arrays A and B (TaqMan Array 6 
Human MicroRNA A v3.0 and B v3.0 Cartd Sets, Applied Biosystems) were used in 7 
a ABI Prism 7900HT sequence detection system (Applied Biosystems). The raw Ct 8 
calues were calculated using RQ manager software and analyzed using DataAssist 9 
software (ABI, Applied Biosystems).  10 
 11 
Cell isolation. 12 
Chondrocytes were isolated from articular cartilage from patients with OA 13 
undergoing total knee arthroplasty. The anonymous use of redundant tissue for 14 
research purposes is part of the standard treatment agreement with patients in the 15 
University Medical Center Utrecht (31). The articular cartilage was minced and 16 
digested in 0.15% (w/v) collagenase (CLS-2, Worthington, Lakewood, NJ) in 17 
Dulbecco’s modified Eagle’s medium (DMEM, Gibco, Paisley, UK) supplemented 18 
with 10% foetal bovine serum (FBS, HyClone, Logan, UT), 100 U/ml penicillin 19 
(Gibco) and 100 µg/ml streptomycin (Gibco) for 16h at 37°C. 20 
The cells were filtered through a 100 µm cell strainer (BD Biosciences, San Diego, 21 
CA) and washed before culturing or miRNA/mRNA isolation. 22 
 23 
Cell culture and transfection 24 
Isolated OA chondrocytes were expanded in T175 tissue culture flasks in DMEM 25 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 8 
supplemented with 10% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, and 10 1 
ng/ml bFGF (R&D, Minneapolis, MN), at 37°C in 5% CO2. At confluency, the cells 2 
were trypsinized using 0.25% trypsin/EDTA (Gibco) and replated. 3 
At passage 2, OA chondrocytes were reverse-transfected with a Pre-mir miRNA 4 
precursor for hsa-miR-148a-5p or a Pre-mir miRNA precursor negative control 5 
(Ambion) using Lipofectamine RNAiMax (Invitrogen, Carlsbad, CA). The reverse-6 
transfection was performed during seeding (density 1.6x106 cells/cm2) on Millicell 7 
filters (0.4 µm PFTE (Millipore, Bedford MA) that were precoated with type II 8 
collagen (type II collagen from chicken sternal cartilage (Sigma, St. Louis, MO)) 9 
(32,33). The final concentration of pre-mir miRNA precursor was 10 nM. The cells 10 
were retransfected after 1 and 2 weeks of culture on filters. 11 
The filters were cultured in DMEM (Gibco) supplemented with 10% FBS, 100 U/ml 12 
penicillin, 100 µg/ml streptomycin and 50 µg/ml ascorbate-2-phosphate (Sigma) and 13 
culture media were renewed every 3 days. 14 
 15 
MicroRNA Real-time PCR.  16 
Total RNA was extracted from chondrocytes with the mirVana miRNA isolation kit 17 
(Ambion) according to the manufacturer’s protocol. The expression of hsa-miR-148a 18 
was verified using a TaqMan microRNA assay for hsa-miR-148a (Applied 19 
Biosystems). MiRNA expression was normalized to RNU44 small nuclear RNA. 20 
  21 
Real-time PCR 22 
Total RNA was isolated from the cells immersed in Trizol (Invitrogen) as described 23 
by the manufacturer. Total RNA (750 ng) was reverse transcribed using an iScript 24 
cDNA Synthesis Kit (Biorad, Hercules, CA). 25 
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Real-time PCR reactions were performed using the SYBRGreen reaction kit 1 
according to the manufacturer’s instructions (Roche Diagnostics, Mannheim, 2 
Germany) in a LightCycler 480 (Roche Diagnostics). The LightCycler reactions were 3 
prepared in 20 ìl total volume with 7 ìl PCR-H2O, 0.5 ìl forward primer (0.2 ìM), 0.5 4 
ìl reverse primer (0.2 ìM), 10 ìl LightCycler Mastermix (LightCycler 480 SYBR 5 
Green I Master; Roche Diagnostics), to which 2 ìl of 5 times diluted cDNA was added 6 
as PCR template. Primers (Invitrogen) used for real-time PCR are listed in Table 1. 7 
Specific primers were designed from sequences available in the data banks, based on 8 
homology in conserved domains between human, mouse, rat, dog and cow (34). The 9 
amplified PCR fragment extended over at least one exon border (except for 18S). 10 
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta 11 
polypeptide (Ywhaz) and 18S were used as housekeeping genes and the gene 12 
expression levels were normalized for the normalization factor calculated with the 13 
equation √(Ywhaz x 18S). With the Light Cycler software (version 4), the crossing 14 
points were assessed and plotted versus the serial dilution of known concentrations of 15 
the standards derived from each gene using Fit Points method. PCR efficiency was 16 
calculated by Light Cycler software and the data were used only if the calculated PCR 17 
efficiency was between 1.85 and 2.0. 18 
 19 
Papain digestion 20 
After 3 weeks of culture, filters were digested at 60°C for 18 h in a papain enzyme 21 
solution consisting of 5 mM L-cysteine, 50 mM Na2EDTA, 0.1 M NaAc, pH 5.53 22 
with 2% (v/v)  papain (Sigma). 23 
 24 
Proteoglycan analysis 25 
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To analyse the proteoglycan content of the regenerated cartilage tissue and the amount 1 
released into the culture medium, a dimethylmethylene blue (DMMB) 2 
spectrophotometric analysis was performed to determine the content of sulphated 3 
glycosaminoglycans (GAGs) (35). DMMB solution and papain digest or medium 4 
sample were mixed and the absorbance was read at 540 nm and 595 nm. As reference, 5 
chondroitin sulfate C (Sigma) was used. The total amount of proteoglycans produced 6 
was defined as the amount of proteoglycans in the papain tissue digest and the amount 7 
of proteoglycans released into the culture medium during the entire culture period. 8 
 9 
DNA content 10 
Total DNA was quantified in papain digests using Quant-iT Picogreen (Invitrogen) 11 
according to the manufacturer’s instructions. Picogreen reagent was added to papain 12 
digest. This was incubated at ambient temperature for 5 min, protected from light. The 13 
fluorescence was measured at ~480 nm excitation and ~520 nm emission and DNA 14 
content determined using lambda DNA as standard.  15 
 16 
Hydroxyproline assay 17 
To analyse the collagen content, hydroxyproline content was determined in papain 18 
digests or medium samples using a modified colorimetric assay (36). In short, freeze-19 
dried papain digests or medium samples were hydrolyzed and the free 20 
hydroxyprolines were oxidized with Chloramine-T for the production of pyrroles. The 21 
addition of Ehrlich's reagent resulted in the formation of chromophores that were 22 
measured at 550 nm and collagen content was determined using gelatin (Sigma) as 23 
standard. The total amount of collagens produced was defined as the amount of 24 
collagens found in the papain digest and the amount of collagens released into the 25 
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culture medium. 1 
 2 
Type II collagen Western blot 3 
After 3 weeks of culture, filters were digested overnight at 4ºC with pepsin 4 
(Worthington, 100 µg/ml in 0.2 M NaCl, 0.5 M acetic acid). The digests and 0.05, 5 
0.025, and 0.005 ug of type II collagen as reference (chicken sternum, Sigma) were 6 
denatured by heating at 95˚C for 5 min in NuPage LDS sample buffer (Invitrogen) 7 
with NuPage reducing agent (Invitrogen). The digests and collagen standards were 8 
resolved by SDS-PAGE (8% resolving gel with 4% stacking gel) and transferred to 9 
nitrocellulose membranes (Biorad). The membranes were blocked in 2% (w/v) BSA 10 
0.1% Tween in phosphate buffered saline (PBS) for 1 h and were then incubated with 11 
the primary antibody for 2 h. Mouse monoclonal anti-type II collagen (MAB1330, 12 
Chemicon, Millipore) was used at 1:1000 dilution. After three washes with 0.1% 13 
Tween in PBS, the membranes were incubated with horseradish peroxidase-14 
conjugated anti-mouse secondary antibody (DakoCytomation, Glostrup, Denmark) at 15 
a 1:5000 dilution for 1 h. Following three washes, immunoreactivity was visualized 16 
using Lumi-Lightplus (Roche Diagnostics). 17 
 18 
Luciferase assay 19 
The 3’ Untranslated regions (3’ UTRs) of type II and type X collagen (COL2A1 and 20 
COL10A1), matrix metallopeptidase 13 (MMP13), A desintegrin and 21 
metalloproteinase with thrombospondin motifs 5 (ADAMTS5) and serpin peptidase 22 
inhibitor, clade H (heat shock protein 47), member 1 (SERPINH1) were amplified by 23 
PCR with DNA oligonucleotides flanked by XhoI and NotI restriction sites (DNA 24 
oligonucleotide sequences are listed in Table 2). The fragments were cloned 25 
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downstream of the renilla luciferase gene into the pSICHECK2 vector (Promega, 1 
Madison, WI) in sense and antisense orientation.  2 
Hela cells were plated into 96-wells plates and cotransfected with the described 3 
luciferase reporter constructs and 50 nM Pre-mir miRNA precursor for hsa-miR-148a 4 
or a Pre-mir miRNA precursor negative control (Ambion) using Lipofectamine 5 
(Invitrogen). Luminescence was measured 48 hours after transfection using Pierce 6 
Renilla-Firefly Luciferase Dual Assay Kit (Thermo scientific, Rockford, Il).  7 
 8 
Collagenase activity assay 9 
To analyse collagenase activity, the Enzcheck Gelatinase/Collagenase Assay Kit 10 
(Invitrogen) was used according to the manufacturer’s instructions. DQ Collagen 11 
Fluorescein conjugate was added to 100 times in reaction buffer (kit component) 12 
diluted conditioned medium. This was incubated for 4 hours at ambient temperature, 13 
protected from light. The fluorescence was measured at ~480 nm excitation and ~520 14 
nm emission and collagenase activity was determined using collagenase type IV from 15 
Clostridium histolyticum (kit component) as standard.  16 
 17 
Statistical analysis 18 
Gene expression data are expressed as mean ± SD of miR-148a transfected versus 19 
mock transfected chondrocytes of target gene expression normalized for the equation 20 
√(Ywhaz x 18S). Differences in expression ratios were tested with a two-tailed t-test 21 
for single group mean and compared to 1 (miR148a transfected / mock transfected = 22 
1, no effect). Data from biochemical assays are expressed in dot plots where every dot 23 
resembles the value of one donor and the mean value of the samples is indicated by a 24 
line. The data were analyzed using a two-tailed paired t-test. The level of significance 25 
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was set at p<0.05. Normal distribution of the data was confirmed using the Shapiro-1 
Wilk test.  2 
 3 
 4 
Results 5 
hsa-miR-148a regulates COL10A1, MMP13 and ADAMTS5 6 
In the scope of performing an extensive miRNA screen between normal and OA 7 
cartilage, we had found that hsa-miR-148a was expressed about ten times less in OA 8 
cartilage compared to normal cartilage. By real-time PCR it was confirmed that hsa-9 
miR-148a levels were 9 fold lower in OA cartilage compared to normal cartilage (Fig. 10 
1A).  11 
TargetScan 6.2 and/or microRNA.org identified COL2A1, COL10A1, MMP13, 12 
ADAMRS5 and SERPINH1 amongst the predicted targets of hsa-miR-148a. The gene 13 
expression levels of these genes were measured in the same RNA in which hsa-miR-14 
148a levels were determined. The expression level of COL2A1 was decreased in the 15 
OA donors (Fig. 1B), the levels of COL10A1, MMP13 and ADAMTS5 were 16 
increased in OA donors (Fig. 1C-1E), and for SERPINH1 no difference was observed 17 
(Fig. 1F).  18 
To investigate the effects of upregulation of hsa-miR-148a, a miRNA precursor (pre-19 
miR) for hsa-miR-148a or a pre-mir negative control was transfected in OA 20 
chondrocytes. Real-Time PCR analysis confirmed that transfection of the pre-miR 21 
increased the expression of hsa-miR-148a compared to transfection with control non-22 
coding pre-miRNA (Fig. 2). The upregulation of hsa-miR-148a expression was 23 
highest 3 days after the initial transfection, with a 5-fold increase compared to the 24 
precursor negative control. Just before the re-transfections at day 7 and 14 and at the 25 
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end of the culture period of 3 weeks, the hsa-miR-148a expression levels were up-1 
regulated about 3.5-fold.  2 
Overexpression of hsa-miR-148a resulted in increased COL2A1, decreased 3 
COL10A1. MMP13 and ADAMTS5, and unchanged SERPINH1 gene expression 4 
levels (Fig. 2). 5 
To analyse the miRNA – mRNA interactions of the predicted target genes, a 6 
luciferase reporter assay was performed. No difference in luciferase activity was 7 
observed between HeLa cells cotransfected with the construct containing the 3’ UTR 8 
of COL2A1 and SERPINH1 and the miRNA precursor for hsa-miR-148a or a miRNA 9 
precursor negative control (Fig. 3). A decrease in luciferase activity was measured in 10 
Hela cells cotransfected with the miRNA precursor for hsa-miR-148a and the 11 
luciferase reporter vector containing the 3’ UTRs of COL10A1, MMP13 and 12 
ADAMTS5 in sense orientation (Fig. 3). No difference was shown when the 3’ UTRs 13 
of COL10A1, MMP13 and ADAMTS5 were cloned into the luciferase reporter vector 14 
in antisense orientation (Fig. 3).  15 
 16 
Overexpression of hsa-miR-148a increases proteoglycan content and decreases 17 
proteoglycan release 18 
Overexpression of hsa-miR-148a had no effect on ACAN gene expression levels, but 19 
did decrease the gene expression levels of the aggrecanase ADAMTS5 (Fig. 2). The 20 
amount of proteoglycans was increased in the tissue generated by hsa-miR-148a 21 
overexpressing OA chondrocytes compared to controls (Fig. 4A), while proteoglycan 22 
release into the culture medium was decreased (Fig. 4B).  23 
No difference was found between chondrocytes overexpressing hsa-miR-148a and 24 
controls in terms of the total amount of proteoglycans produced, as determined by 25 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 15 
adding up the amount found in the deposited matrix at the end of culture period and 1 
the total amount released into the medium during culture (Fig. 4C).  2 
 3 
Overexpression of hsa-miR-148a increases collagen II expression at the mRNA and 4 
protein level and decreases the expression of type X collagen and MMP-13 5 
However, overexpression of hsa-miR-148a resulted in increased COL2A1 gene 6 
expression levels and the gene expression levels of COL10A1 and the collagenase 7 
MMP13 were decreased (Fig. 2). No effect was shown on gene expression levels of 8 
COL1A1 and the collagen chaperone SERPINH1 (Fig. 2).  9 
The amount of collagen was increased in the matrix deposited by hsa-miR-148a 10 
overexpressing OA chondrocytes compared to controls (Fig. 5A), while the amount of 11 
collagen released into the culture medium was decreased (Fig. 5B).  12 
In contrast to the lack of effect on total proteoglycan production, the total amount of 13 
collagen produced was increased by hsa-miR-148a overexpressing OA chondrocytes 14 
compared to controls (Fig 5C).  15 
Collagenase activity was decreased in the culture medium of the hsa-miR-148a 16 
overexpressing OA chondrocytes (Fig. 5D). 17 
To verify whether type II collagen was also specifically upregulated at the protein 18 
level, an immunoblot for type II collagen was performed on the collagen extracted 19 
from the cultures, confirming the higher deposition of type II collagen by the hsa-20 
miR-148a overexpressing OA chondrocytes compared to the mock-transfected OA 21 
chondrocytes (Fig. 5E).  22 
 23 
Discussion 24 
In this study hsa-miR-148a, expressed at lower levels in OA cartilage compared to 25 
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healthy cartilage, is suggested to play an important role in cartilage regeneration. 1 
Overexpressing hsa-miR-148a in OA chondrocytes increases extracellular matrix 2 
deposition by these cells; not only proteoglycan, but also the collagen and specifically 3 
type II collagen content was increased. In addition, matrix degradation was reduced, 4 
as reflected by a decreased release of proteoglycans during culture, which was 5 
accompanied by downregulation of MMP13, COL10A1 and ADAMTS5, predicted 6 
and confirmed targets of miR-148a.  7 
Surprisingly, COL2A1, another postulated target gene was found to be increased upon 8 
overexpression of hsa-miR-148a in OA chondrocytes. This suggests that COL2A1 is 9 
not a direct target of hsa-miR-148a, as miRNAs are by default negative regulators of 10 
gene expression. A luciferase reporter assay also showed no interaction between miR-11 
148a and COL2A1. However, hsa-miR-148a might target a repressor of COL2A1 as 12 
was also suggested for miR-675 (28).  13 
The gene expression patterns for collagen and aggrecan were also reflected at the 14 
protein level. The gene expression level of aggrecan, the main proteoglycan in the 15 
cartilaginous extracellular matrix, was unchanged. Although an increased 16 
proteoglycan content was found after culturing, total proteoglycan production did not 17 
increase. The decreased proteoglycan release in combination with the decreased 18 
ADAMTS5 expression suggests that the increase in proteoglycan content was caused 19 
by a diminished breakdown, resulting in increased retention, rather than an increase in 20 
synthetic activity.  21 
The increased total collagen and specifically type II collagen production found upon 22 
overexpression of miR-148a was in line with the increased gene expression levels of 23 
COL2A1. Next to a generalised increase in synthetic activity, a higher portion of 24 
collagen was found in the deposited matrix compared to collagen released into the 25 
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culture medium. This coincided with decreased gene expression of MMP13, the main 1 
enzyme involved in cartilage collagen degradation. This is supported by the decreased 2 
collagenase activity found in the culture medium of the hsa-miR-148a overexpressed 3 
chondrocytes. So, collagen production was not only increased but its degradation was 4 
also inhibited. Most likely this increased deposition of collagen was responsible for 5 
the increase in proteoglycan content found, as an intact collagen network is required 6 
for the retention of proteoglycans inside the cartilage matrix (37). 7 
In addition to the stimulatory effects on cartilage matrix formation, the 8 
downregulation of COL10A1 gene expression levels by miR-148a overexpression 9 
suggests further reversal of the OA chondrocytic phenotype, as hypertrophic 10 
differentiation characterised by increased COL10A1 expression levels is a hallmark of 11 
OA.  12 
In addition to COL2A1 another predicted miR-148a target that was not affected in 13 
line with the sequence-based prediction was SERPINH1, a collagen-specific 14 
chaperone. This protein is required for proper intracellular protein folding of the 15 
collagens and decreased SERPINH1 levels might lead to improper collagen folding 16 
resulting in intracellular accumulation and degradation of collagens. However, miR-17 
148a after all did not seem to target SERPINH1 and increased production and 18 
deposition of collagens by miR-148a overexpressed OA chondrocytes suggests that 19 
are no complications with the intracellular folding of collagens. This was confirmed 20 
in a luciferase reporter assay, showing that miR-148a interacts with MMP13, 21 
COL10A1 and ADAMTS5, but not with SERPINH1 or COL2A1. 22 
In addition to modulating matrix protein expression by binding target mRNA or 23 
repressor mRNA of matrix gene expression, another mechanism by which hsa-miR-24 
148a may target cartilage metabolism, is by affecting methylation pathways, as miR-25 
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148a directly targets DNA methyltransferase 1 (DNMT1) (38-41). Lower expression 1 
of miR-148a could increase DNMT1 expression and attenuate DNA hypomethylation. 2 
It was suggested that changes in DNA methylation also play a role in the gene 3 
expression patterns observed in OA (10), and thus hsa-miR-148a might also modulate 4 
cartilage matrix production through a more general DNA methylation-based way.  5 
Besides hsa-miR-148a, several other miRNAs are already found to be differentially 6 
expressed in OA (18-21). Hsa-miR-140 is one of the most studied miRNAs with 7 
respect to cartilage and its expression is significantly lower in OA cartilage compared 8 
to healthy cartilage (22-24). Also hsa-miR-27 and hsa-miR-146a levels are 9 
significantly lower in OA cartilage compared to healthy cartilage and they are found 10 
to regulate the expression of MMP13 (25-27). The gene expression of type II collagen 11 
(COL2A1) is indirectly regulated by hsa-miR-675 and miR-145 directly targets SOX9 12 
(28,29). 13 
Although the abovementioned miRNAs were functionally analysed, the effects of 14 
modulating the expression of these miRNAs on actual cartilage regeneration, in 15 
particular at the protein level, are unknown. The current study is the first investigating 16 
the effect of modulating the expression of a specific miRNA on the production and 17 
degradation of the main components of cartilage, the proteoglycans and collagens.  18 
In the current study, cartilage production was shown to be enhanced by 19 
overexpression of hsa-miR-148a in OA chondrocytes, which, in addition to providing 20 
information on mechanisms in the pathogenesis and maintenance of OA, may render 21 
this miRNA a target for a potential therapy for OA or to induce cartilage repair. 22 
Several clinical trials are already ongoing for miRNA-based treatment of hepatitis C 23 
(42), liver cancer (43,44), and heart failure (45). However, a drawback for miRNA-24 
based treatment for cartilaginous tissues is the relative inaccessibility of chondrocytes. 25 
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Since cartilage is avascular and the chondrocytes are embedded in a dense and 1 
charged extracellular matrix, it may be difficult to transfect chondrocytes in the native 2 
tissue.  However, many advances in transfection of cartilage in vivo are currently 3 
being achieved (46-50), increasing the possibility of application of miRNA in 4 
targeting cartilaginous tissues. 5 
In conclusion, overexpression of hsa-miR-148a stimulated the production of 6 
collagens, specifically type II collagen, and enhanced the retention and deposition of 7 
collagen and proteoglycans, respectively, in cartilage matrix deposited by OA 8 
chondrocytes.  Hsa-miR-148a may be a potential target for the treatment of OA, as it 9 
promotes cartilage production and prevents cartilage degradation and hypertrophy.  10 
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Table 1. Oligonucleotide sequences used for real time PCR  1 
Target gene Oligonucleotide sequence Annealing temperature 
(°C) 
Product 
size (bp) 
Fw  5' GTAACCCGTTGAACCCCATT 3' 57 151 18S 
  Rev  5' CCATCCAATCGGTAGTAGCG 3'     
Fw  5' GATGAAGCCATTGCTGAACTTG 3' 56 229 YWHAZ 
  Rev  5' CTATTTGTGGGACAGCATGGA 3'     
Fw  5' CAACTACCCGGCCATCC 3' 57 160 ACAN 
  Rev  5' GATGGCTCTGTAATGGAACAC 3'     
Fw  5' TCCAACGAGATCGAGATCC 3' 57 191 COL1A1 
  Rev  5' AAGCCGAATTCCTGGTCT 3'     
Fw  5' AGGGCCAGGATGTCCGGCA 3' 56 195 COL2A1 
  Rev  5' GGGTCCCAGGTTCTCCATCT 3'     
Fw 5' CACTACCCAACACCAAGACA 3' 56 225 COL10A1 
Rev 5' CTGGTTTCCCTACAGCTGAT 3'   
Fw  5' GGAGCATGGCGACTTCTAC 3' 56 208 MMP13 
Rev  5' GAGTGCTCCAGGGTCCTT 3'     
Fw  5’ GCCAGCGGATGTGTGCAAGC 3’ 57 130 ADAMTS5 
Rev  5’ ACACTTCCCCCGGACGCAGA  3’   
Fw  5' TGATGATGCACCGGACAG 3' 57 212 SERPINH1 
  Rev  5' GGAGATGGCAACAGCCTTC 3'     
Forward (Fw) and reverse (Rev) primers for YWHAZ, tyrosine 3-2 
monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide; 3 
ACAN, aggrecan; COL1A1, α1(I)procollagen; COL2A1, α1(II)procollagen; 4 
COL10A1, α1(X)procollagen; MMP13, matrix metallopeptidase 13; ADAMTS5, a 5 
disintegrin and metalloproteinase with thrombospondin motifs 5; SERPINH1, serpin 6 
peptidase inhibitor, clade H (heat shock protein 47), member 1. 7 
 8 
 9 
 10 
 11 
 12 
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Table 2. Oligonucleotide sequences used for amplifying 3’ untranslated regions 1 
3’ UTR of target gene Oligonucleotide sequence 
Fw CCGCTCGAGAAACCTGAACCCAGAAAC COL2A1 sense 
Rev CGTACGCCGGCGGTACTTTCCAATAATCTTTTC 
FW GCATGCGGCCGCAAACCTGAACCCAGAAACAAC COL2A1 antisense 
Rev CGTACTCGAGGTACTTTCCAATAATCTTTTC 
Fw CCGCTCGAGGTACACACAGAGCTAATCTAAATC COL10A1 sense 
Rev CGTACGCCGGCGCACTTTATTGTCCTACTTTTTTATTAAC 
Fw GCATGCGGCCGCGTACACACAGAGCTAATCTAAATC COL10A1 antisense 
Rev CGTACTCGAGCACTTTATTGTCCTACTTTTTTATTAAC 
Fw CCGCTCGAGGTGTCTTTTTAAAAATTGTTATT MMP13 sense 
Rev CGTACGCCGGCGCTGTTGAAAATATATTTTTATTATAAAC 
Fw GCATGCGGCCGCGTGTCTTTTTAAAAATTGTTATT MMP13 antisense 
Rev CGTACTCGAGCTGTTGAAAATATATTTTTATTATAAAC 
Fw CCGCTCGAGCCTGTGGTTATGATCTTATGCAC ADAMTS5 sense 
Rev CGTACGCCGGCGACTTTAACCTAGTTTACAATTTATAT 
Fw GCATGCGGCCGCCCTGTGGTTATGATCTTATGCAC ADAMTS5 antisense 
Rev CGTACTCGAGACTTTAACCTAGTTTACAATTTATAT 
Fw CCGCTCGAGGGCCTCAGGGTGCACACAGGATG SERPINH1 sense 
Rev CGTACGCCGGCGCCACGCTCCAACAAAATGTCATTGG 
Fw GCATGCGGCCGCGGCCTCAGGGTGCACACAGGATG SERPINH1 antisense 
Rev CGTACTCGAGCCACGCTCCAACAAAATGTCATTGG 
Forward (Fw) and reverse (Rev) primers for COL2A1, α1(II)procollagen; COL10A1, 2 
α1(X)procollagen; MMP13, matrix metallopeptidase 13; ADAMTS5, a disintegrin 3 
and metalloproteinase with thrombospondin motifs 5; SERPINH1, serpin peptidase 4 
inhibitor, clade H (heat shock protein 47), member 1. 5 
 6 
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Figure legends: 1 
 2 
Figure 1: Real-time PCR was performed for hsa-miR-148a, type II collagen 3 
(COL2A1), type X collagen (COL10A1), matrix metallopeptidase 13 (MMP13), a 4 
disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) and 5 
serpin peptidase inhibitor, clade H (heat shock protein 47), member 1 (SERPINH1) on 6 
reverse transcribed RNA isolated from osteoarthritic cartilage (7 donors) and normal 7 
cartilage (7 donors). The data are presented in a dot plot where every dot resembles 8 
the value of one donor. The mean value of the samples is indicated by a line. Data are 9 
shown as mean ± SD. ***: p<0.001.  10 
 11 
Figure 2: Real-time PCR was performed on reverse transcribed RNA isolated from 12 
OA chondrocytes transfected with a pre-mir miRNA precursor for hsa-miR-148a or a 13 
pre-miR miRNA precursor negative control after 3, 7, 14 and 21 days in a 14 
regeneration culture. Expression levels of hsa-miR-148a (148a), aggrecan (ACAN), 15 
type I collagen (COL1A1), type II collagen (COL2A1), type X collagen (COL10A1), 16 
matrix metallopeptidase 13 (MMP13), a disintegrin and metalloproteinase with 17 
thrombospondin motifs 5 (ADAMTS5) and serpin peptidase inhibitor, clade H (heat 18 
shock protein 47), member 1 (SERPINH1) were measured. The results are presented 19 
as expression levels of hsa-miR-148a transfected OA chondrocytes relative to 20 
negative control transfected OA chondrocytes. Data are shown as mean ± SD. **: 21 
p<0.01; ***: p<0.001. 22 
 23 
Figure 3: HeLa cells were cotransfected with 50 nM pre-mir miRNA precursor for 24 
hsa-miR-148a or pre-miR miRNA precursor negative control (mock) and 25 
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pSICHECK2 containing the 3’ unstranslated regions (UTR) of type II collagen 1 
(COL2A1), type X collagen (COL10A1), matrix metallopeptidase 13 (MMP13), a 2 
disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) and 3 
serpin peptidase inhibitor, clade H (heat shock protein 47), member 1 (SERPINH1) in 4 
sense and antisense orientation. Firefly and Renilla luciferase were measured 48 hours 5 
after transfection. Data are shown as mean ± SD. *: p<0.05; **: p<0.01. 6 
 7 
Figure 4: Proteoglycan content (A), release (B), and total production (C) (determined 8 
as glycosaminoglycans (GAG)) (normalized for the DNA content) were determined 9 
after 21 days in cultures of OA chondrocytes transfected with a pre-miR miRNA 10 
precursor negative control (mock) or a pre-mir miRNA precursor for hsa-miR-148a 11 
(miR-148a). The data are presented in a dot plot where every dot resembles the value 12 
of one donor. The mean value of the samples is indicated by a line. *: p<0.05; 13 
***:p<0.001. 14 
 15 
Figure 5: Collagen content (A), release (B), and total production (C) (determined as 16 
hydroxyproline (normalized for the DNA content)), collagenase activity (D) and type 17 
II collagen (E, determined by immunoblot) were determined after 21 days in cultures 18 
of OA chondrocytes transfected with a pre-miR miRNA precursor negative control 19 
(mock) or a pre-mir miRNA precursor for hsa-miR-148a (miR-148a). The data are 20 
presented in a dot plot where every dot resembles the value of one donor. The mean 21 
value of the samples is indicated by a line. Figure E: The first lane contains a protein 22 
ladder, the following three standards of 0.005, 0.025, and 0.05 µg type II collagen. *: 23 
p<0.01; ***: p<0.001. 24 
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